Literature DB >> 22105374

Apert syndrome mutant FGFR2 and its soluble form reciprocally alter osteogenesis of primary calvarial osteoblasts.

Hiroyuki Suzuki1, Naoto Suda, Momotoshi Shiga, Yukiho Kobayashi, Masataka Nakamura, Sachiko Iseki, Keiji Moriyama.   

Abstract

Apert syndrome is characterized by craniosynostosis and syndactyly, and is predominantly caused by mutation of either S252W or P253W in the fibroblast growth factor receptor (FGFR) 2 gene. In this study, we characterized the effects of one of the mutations (S252W) using primary calvarial osteoblasts derived from transgenic mice, Ap-Tg and sAp-Tg, that expressed an Apert-type mutant FGFR2 (FGFR2IIIc-S252W; FGFR2IIIc-Ap), and the soluble form (extracellular domain only) of the mutant FGFR2 (sFGFR2IIIc-Ap), respectively. Compared to WT-derived osteoblasts, osteoblasts from Ap-Tg mouse showed a higher proliferative activity and enhanced differentiation, while those from sAp-Tg mouse exhibited reduced potential for proliferation and osteogenic differentiation. When transplanted with β-tricalcium phosphate (β-TCP) granules into immunodeficient mice, Ap-Tg-derived osteoblasts showed a higher bone forming capacity, whereas sAp-Tg-derived osteoblasts were completely deficient for this phenotype. Phosphorylation of extracellular signal-regulated kinase (ERK), MEK, PLCγ, and p38 was increased in Ap-Tg-derived osteoblasts, whereas phosphorylation of these signaling molecules was reduced in sAp-Tg-derived osteoblasts. Interestingly, when these experiments were carried out using osteoblasts from the mice generated by crossing Ap-Tg and sAp-Tg (Ap/sAp-Tg), which co-expressed FGFR2IIIc-Ap and sFGFR2IIIc-Ap, the results were comparable to those obtained from WT-derived osteoblasts. Taken together, these results indicate that osteoblasts expressing FGFR2IIIc-Ap proliferate and differentiate via highly activated MEK, ERK, and p38 pathways, while these pathways are suppressed in osteoblasts expressing sFGFR2IIIc-Ap. Our findings also suggest that altered FGFR2IIIc signaling in osteoblasts is mostly responsible for the phenotypes seen in Apert syndrome, therefore these osteoblast cell lines are useful tools for investigating the pathogenesis of Apert syndrome.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22105374     DOI: 10.1002/jcp.24021

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

Review 1.  The molecular and cellular basis of Apert syndrome.

Authors:  Chao Liu; Yazhou Cui; Jing Luan; Xiaoyan Zhou; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2013-11

Review 2.  Research advances in Apert syndrome.

Authors:  Satrupa Das; Anjana Munshi
Journal:  J Oral Biol Craniofac Res       Date:  2017-05-25

Review 3.  Genetic determinants of syndactyly: perspectives on pathogenesis and diagnosis.

Authors:  Afraah Cassim; Dineshani Hettiarachchi; Vajira H W Dissanayake
Journal:  Orphanet J Rare Dis       Date:  2022-05-12       Impact factor: 4.303

Review 4.  Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies.

Authors:  Pierre J Marie
Journal:  Cell Mol Life Sci       Date:  2014-12-09       Impact factor: 9.261

Review 5.  2b or Not 2b: How Opposing FGF Receptor Splice Variants Are Blocking Progress in Precision Oncology.

Authors:  Richard J Epstein; Li Jun Tian; Yan Fei Gu
Journal:  J Oncol       Date:  2021-04-30       Impact factor: 4.375

Review 6.  Fibroblast growth factor signaling in skeletal development and disease.

Authors:  David M Ornitz; Pierre J Marie
Journal:  Genes Dev       Date:  2015-07-15       Impact factor: 11.361

7.  Characterization of dental pulp stem cells isolated from a patient diagnosed with Crouzon syndrome.

Authors:  Daisuke Torii; Tomoko Kobayashi; Tetsuro Horie; Takeo W Tsutsui
Journal:  J Cell Physiol       Date:  2021-01-01       Impact factor: 6.384

Review 8.  Insights and future directions of potential genetic therapy for Apert syndrome: A systematic review.

Authors:  Nisreen Mohammed Al-Namnam; Soher Nagi Jayash; Firdaus Hariri; Zainal Ariff Abdul Rahman; Mohammed Abdullah Alshawsh
Journal:  Gene Ther       Date:  2021-02-22       Impact factor: 5.250

9.  Therapeutic effect of nanogel-based delivery of soluble FGFR2 with S252W mutation on craniosynostosis.

Authors:  Masako Yokota; Yukiho Kobayashi; Jumpei Morita; Hiroyuki Suzuki; Yoshihide Hashimoto; Yoshihiro Sasaki; Kazunari Akiyoshi; Keiji Moriyama
Journal:  PLoS One       Date:  2014-07-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.